GlassScriptPhysician profile
Ray M Braquet
NPI 1427230291
$3,106.70
in general payments reported to CMS, 2019-2025
29 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $498 · 2021: $680 · 2022: $654 · 2023: $506 · 2024: $168 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.53 | 2019-2023 | Lo Loestrin Fe |
| Daiichi Sankyo INC. | $399.46 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $287.86 | 2019-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $181.54 | 2019-2022 | |
| Exeltis, USA INC. | $164.35 | 2022-2025 | Slynd |
| Aspira Women'S Health INC | $157.33 | 2021 | |
| Avion Pharmaceuticals | $144.45 | 2019-2022 | |
| Pfizer INC. | $138.99 | 2019-2025 | |
| Hologic Sales and Service, LLC | $113.30 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Aptima |
| Myovant Sciences INC. | $110.51 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $103.99 | 2020-2022 | |
| Organon LLC | $90.44 | 2021-2025 | Nexplanon, Jada System |
| Mission Pharmacal Company | $70.80 | 2019-2020 | |
| Evofem Biosciences, INC. | $70.21 | 2022-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $68.39 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $61.40 | 2022-2024 | |
| Biogen, INC. | $52.30 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $44.91 | 2023-2025 | Accrufer |
| Allergan, INC. | $28.72 | 2019 | |
| Novo Nordisk INC | $28.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $25.82 | 2020-2021 | |
| Exact Sciences Corporation | $24.95 | 2023 | Cologuard Collection Kit |
| Teleflex LLC | $23.95 | 2025 | Quikclot |
| Biohaven Pharmaceuticals, INC. | $22.65 | 2020 | |
| Coopersurgical, INC. | $21.83 | 2024 | Endosee |
| Intra-Sana Laboratories | $14.97 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.15 | 2021 | |
| Duchesnay USA Incorporated | $11.51 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Braquet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.